A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea

This study has been completed.
Information provided by:
ClinicalTrials.gov Identifier:
First received: March 25, 2005
Last updated: March 4, 2015
Last verified: March 2015

Approximately 520 patients will be entered into this study taking place throughout the US and Canada. This study aims to determine if an investigational drug is safe and effective for treating symptoms of C. difficile-associated diarrhea (CDAD) and lowering the risk of repeat episodes of CDAD. The investigational drug will be evaluated in comparison to current standard antibiotic treatment, so all patients will receive active medication. All study related care is provided including doctor visits, physical exams, laboratory tests and study medication. Total length of participation is approximately 6 weeks.

Condition Intervention Phase
Clostridium Enterocolitis
Pseudomembranous Colitis
Drug: tolevamer potassium-sodium (GT267-004)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind Study of GT267-004 Versus Vancomycin, and GT267-004 Versus Metronidazole, in Patients With C.Difficile - Associated Diarrhea

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Resolution of diarrhea

Secondary Outcome Measures:
  • Time to resolution of diarrhea
  • Recurrence rate
  • Number of stools
  • Average stool consistency
  • Treatment success

Estimated Enrollment: 520
Study Start Date: March 2005
Study Completion Date: February 2007

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age
  • The presence of CDAD at the time of enrollment with no other likely etiology for the diarrhea
  • Less than or equal to 48 hours of treatment with metronidazole, vancomycin or other antibacterial therapy specific for CDAD
  • Baseline serum potassium > 3.0 mmol (meq)/L
  • Patient considered sufficiently stable clinically to likely complete a 6 week study period
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00106509

  Show 140 Study Locations
Sponsors and Collaborators
Genzyme, a Sanofi Company
Study Director: Medical Monitor Genzyme, a Sanofi Company
  More Information

No publications provided by Sanofi

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Medical Monitor, Genzyme Corporation
ClinicalTrials.gov Identifier: NCT00106509     History of Changes
Other Study ID Numbers: GD3-170-301
Study First Received: March 25, 2005
Last Updated: March 4, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Sanofi:
Clostridium Enterocolitis
Pseudomembranous Colitis
Clostridium difficile-associated diarrhea
C. difficile

Additional relevant MeSH terms:
Enterocolitis, Pseudomembranous
Bacterial Infections
Clostridium Infections
Digestive System Diseases
Gastrointestinal Diseases
Gram-Positive Bacterial Infections
Intestinal Diseases
Signs and Symptoms
Signs and Symptoms, Digestive
Anti-Infective Agents
Antiparasitic Agents
Antiprotozoal Agents
Pharmacologic Actions
Radiation-Sensitizing Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 09, 2015